Muhammad Ishrat Husain
Psychiatrist and Assistant Professor of Psychiatry at the University of Toronto
Data updated
Research Footprint
Muhammad Ishrat Husain appears in 9 tracked papers (2022–2026), most studied alongside Psilocybin, LSD and Ketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Anxiety Disorders.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Roger McIntyre, Jonathan Rosenblat and Guy Goodwin.
Background & Research
Muhammad Ishrat Husain is a psychiatrist affiliated with the Centre for Addiction and Mental Health and the University of Toronto. His research focuses on mood disorders, treatment-resistant depression, and emerging interventions including psilocybin-assisted therapy and ketamine. He has published on psychedelic trial methodology, microdosing trends, and the antidepressant effects of psilocybin.
Key Impact
He is a leading academic psychiatrist contributing to clinical trial, systematic review, and meta-analytic research on psilocybin and other novel treatments for depression and related disorders.
Collaboration Network
44 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Muhammad Ishrat Husain is associated with.
Centre for Addiction and Mental Health
hospitalThe Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health teaching hospital, located in Toronto, Ontario. CAMH is a major hub for psychedelic research in Canada, running trials on psilocybin, MDMA, and ketamine across a range of psychiatric indications.
View stakeholder →University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →